lisdexamfetamine Capsules 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Comments
Dossier availability date: Q1 2025
Manufacturer #10620
A pharmaceutical manufacturer based in the EU that is active in 60+ countries selling its products in Europe, Africa, the Middle East, North America, LATAM, and Asia for 50+ years. The main therapeutic areas include cardiovascular, rheumatology, nephrology, and central nervous system. The main dosage forms are oral solid and multi-dose powder. They are produced in GMP-compliant manufacture.

Manufacturer usually replies in 17 days

None